admin

Foster City, CA, Shanghai and Hangzhou, China, May 20, 2021 — Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that Apollomics Shanghai Branch has been officially opened and started its operations at Zhangjiang Hi-Tech Park, Pudong District, Shanghai. Dr. Guoliang Yu, the company’s Co-Founder, […]

– Fibrogen veteran brings global R&D expertise to Management Team – – Merck KGaA Executive Sophie (Zhengjie) Sun named Senior Vice President, Corporate Development bringing partnership, strategy and commercialization expertise – Foster City, CA, and Hangzhou, China, March 9, 2021 — Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and

TYG100 utilizes proprietary S-TIR™ technology platform enabling specific B cell and T cell responses against tumor antigens  FOSTER CITY, Calif. and HANGZHOU, ZHEJIANG, CHINA, February 12, 2021 – Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced an exclusive license agreement for the development

Agreement will expand clinical development for a potent and selective small molecule targeting TBL1, a downstream target in the Wnt/b-catenin signaling pathway FOSTER CITY, Calif. and HANGZHOU, China and HOUSTON, Texas, February 10, 2021 – Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and Iterion

– Apollomics licenses worldwide rights (ex-China, Hong Kong and Taiwan) to develop and commercialize EO1001 –  – EO1001 is an irreversible, pan-erbB inhibitor of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) – FOSTER CITY, Calif. and HANGZHOU, China and MENLO PARK, CA, February 9, 2021 – Apollomics, Inc., an innovative biopharmaceutical company committed to the

Foster City, CA, Hangzhou, China, Gaithersburg, MD,  January 7, 2021 — Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and GlycoMimetics (Nasdaq: GLYC), today announced APL-106 (uproleselan) has been granted Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE)

Foster City, CA, and Hangzhou, China, November 11, 2020 – Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of new tumor-targeting agents and immuno-oncology agents and their combination therapies, today announced that APL-102 has received China Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) of the National

– Financing led by Ping An Capital – – Phase 2 SPARTA Trial for APL-101 Now Enrolling – – Phase 3 Clinical Trial to begin in China for APL-106 (Uproleselan) –  Foster City, CA, and Hangzhou, China, November 6, 2020 — Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of oncology combination